Difference between revisions of "Timeline of diphtheria"
From Timelines
| Line 24: | Line 24: | ||
|- | |- | ||
| 1894 || Medical development || The production and marketing of the diphtheria therapeutic serum begins in Germany.<ref name="Emil von Behring: The Founder of Serum Therapy"/> || [[wikipedia:Germany|Germany]] | | 1894 || Medical development || The production and marketing of the diphtheria therapeutic serum begins in Germany.<ref name="Emil von Behring: The Founder of Serum Therapy"/> || [[wikipedia:Germany|Germany]] | ||
| + | |- | ||
| + | | 1901 || Medical development || [[wikipedia:Emil von Behring|Emil von Behring]], for the first time, uses a diphtheria innoculation of bacteria with reduced virulence, hoping with this active immunization to help the body also produce antitoxins.<ref name="Emil von Behring: The Founder of Serum Therapy"/> || [[wikipedia:Germany|Germany]] | ||
|- | |- | ||
| 1921 || Report || 206,000 cases of diphtheria and 15,520 deaths are recorded in the United States.<ref name="Diphtheria: The Plague Among Children">{{cite web|title=Diphtheria: The Plague Among Children|url=https://www.historyofvaccines.org/timeline?timeline_categories[]=50|website=historyofvaccines.org|accessdate=8 May 2017}}</ref> || [[wikipedia:United States|United States]] | | 1921 || Report || 206,000 cases of diphtheria and 15,520 deaths are recorded in the United States.<ref name="Diphtheria: The Plague Among Children">{{cite web|title=Diphtheria: The Plague Among Children|url=https://www.historyofvaccines.org/timeline?timeline_categories[]=50|website=historyofvaccines.org|accessdate=8 May 2017}}</ref> || [[wikipedia:United States|United States]] | ||
Revision as of 11:37, 9 May 2017
| Year/period | Key developments |
|---|---|
| 19th century | Diphtheria infection grows significantly late in the century to become one of the major causes of death, fuelled by the industrial revolution and increasingly crowded urban centers.[1] |
Full timeline
| Year/period | Type of event | Event | Present time geographical location |
|---|---|---|---|
| 5th century BC | Scientific development | Diphtheria is first described by Greek physician Hippocrates.[2] | Greece |
| 1600s | Scientific development | Medical reports of a "deadly" strangulation disease first appear early in the century, and emerges as a greater threat with the growth.[1] | |
| 1826 | Scientific development | French physician Pierre Bretonneau gives diphtheria its official name diphtérite, derived from the Greek word for "leather" or "hide", which describes the pseudomembrane in the throat of the victims.[1][3] | |
| 1884 | Scientific development | German bacteriologist Friedrich Loeffler first grows diphtheria bacterium corynebacterium diphtheriae in pure culture.[4] | Germany |
| 1890 | Medical development | German physiologist Emil von Behring develops the first effective therapeutic serum against diphtheria. In 1901 Von Bering would be awarded the first Nobel Prize in Physiology or Medicine for this work.[5][6] | Germany |
| 1891 | Medical development | The first successful therapeutic serum treatment of a child suffering from diphtheria is performed.[5] | |
| 1894 | Medical development | The production and marketing of the diphtheria therapeutic serum begins in Germany.[5] | Germany |
| 1901 | Medical development | Emil von Behring, for the first time, uses a diphtheria innoculation of bacteria with reduced virulence, hoping with this active immunization to help the body also produce antitoxins.[5] | Germany |
| 1921 | Report | 206,000 cases of diphtheria and 15,520 deaths are recorded in the United States.[7] | United States |
| 1923 | Medical development | Diphtheria toxoid is licensed; prepared from inactivated bacterial toxin that has lost its toxicity but retains its antitoxin producing properties.[6] | |
| 1924 | Scientific development | French biologist Gaston Ramon, working at Pasteur Institute, discoveres diphtheria and tetanus toxoid, then referred to as anatoxins.[8] | France |
| 1947 | Medical development | Combination diphtheria and tetanus toxoids for pediatric use is first licensed in the United States.[6] | United States |
| 1953 | Medical development | Tetanus and diphtheria toxoids (adult formulation) are first licensed in the United States, after the concentration of diphtheria toxoid is reduced.[6] | United States |
| 1974 | Epidemic | Diphtheria epidemic breaks out in Lisbon. 500 persons are involved, and about 40 deaths are recorded.[4] | Portugal |
| 1982 | Epidemic | 5 deaths are recorded in Germany during a diphtheria outbreak.[4] | Germany |
| 1996 | Medical development | Lederle Laboratories licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Acel-Imune, for use as the first through fifth doses in the series.[6] | |
| 1997 | Medical development | British pharmaceutical company SmithKline Beecham licenses Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed), for the first four doses of the series.[6] | |
| 1998 | Medical development | North American Vaccine Inc licenses Certiva (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed), for boosting immunization of infants and children.[6] | |
| 1999 | Medical development | Connaught Laboratories licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Tripedia.[6] | |
| 2002 | Medical development | British pharmaceutical GlaxoSmithKline licenses Pediarix, a vaccine combining diphtheria, tetanus, acellular pertussis, inactivated polio, and hepatitis B antigens.[6] | |
| 2002 | Medical development | Aventis Pasteur licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Daptacel.[6] | |
| 2004 | Medical development | Aventis Pasteur licenses vaccine Decavac, indicated for active immunization against tetanus and diphtheria.[6][9] | |
| 2005 | Medical development | Sanofi Pasteur licenses Menactra, the first meningococcal polysaccharide (Serogroups A, C, Y and W-135) diphtheria toxoid conjugate vaccine. This would be the first immunogenic meningococcal vaccine indicated for children younger than 2 years of age.[6] | |
| 2007 | Report | 4,190 cases of diphtheria are reported globally.[7] | |
| 2011 | Medical development | United States Food and Drug Administration approves Boostrix (developed by GlaxoSmithKline) to prevent tetanus, diphtheria, and pertussis in older people.[6] | United States |
See also
- ↑ 1.0 1.1 1.2 "The strangler". museumofhealthcare.ca. Retrieved 9 May 2017.
- ↑ "Diphtheria". medscape.com. Retrieved 8 May 2017.
- ↑ "Pierre Bretonneau". historyofvaccines.org. Retrieved 9 May 2017.
- ↑ 4.0 4.1 4.2 KWANTES, W. "Diphtheria in Europe" (PDF). nih.gov. Retrieved 8 May 2017.
- ↑ 5.0 5.1 5.2 5.3 "Emil von Behring: The Founder of Serum Therapy". nobelprize.org. Retrieved 9 May 2017.
- ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 "Vaccine Timeline". immunize.org. Retrieved 8 May 2017.
- ↑ 7.0 7.1 "Diphtheria: The Plague Among Children". historyofvaccines.org. Retrieved 8 May 2017.
- ↑ Medical Sciences - Volume I (B.P. Mansourian, S.M. Mahfouz, A. Wojtezak ed.). Retrieved 9 May 2017.
- ↑ "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). vaccineshoppe.com. Retrieved 8 May 2017.
